<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Gurbel, Paul</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">First Large-Scale Platelet Function Evaluation in an Acute Coronary Syndrome Trial: The Trilogy ACS-Platelet Function Substudy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">In a platelet function substudy of A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects [TRILOGY ACS; NCT00699998] trial, patients with an acute coronary syndrome treated with prasugrel experienced significantly lower platelet reactivity compared with patients treated with clopidogrel. However, there was no relationship between platelet reactivity and the occurrence of ischemic outcomes, nor were there significant differences in the rates of the composite endpoint of cardiovascular death, myocardial infarction and stroke, or TIMI major bleeding between the 2 treatment groups enrolled in the platelet function substudy.</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>